Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343135 | 0.81 | MAPT (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8860523 | 0.81 | MAPT (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL73063 | 0.80 | HDAC3 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10504383 | 0.80 | HDAC3 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8720078 | 0.79 | MEN1 (0.54) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL7255208 | 0.79 | CYP1A2 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28325099 | 0.79 | MAPT (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13770005 | 0.79 | MAPT (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11625335 | 0.78 | HDAC3 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL73603 | 0.78 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905274-B2 | Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2024-02-20 | — | — | US | disclosed |
| US-20210395231-A1 | RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3770148-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2021-01-27 | — | — | EP | disclosed |
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
| EP-1472250-B1 | ANTICHOLINERGIC AGENTS, METHOD FOR PRODUCING THE SAME AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-7851483-B2 | administering a salt of 7-[(2,2-diphenylpropanoyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0~2,4~]nonane and a steroid selected from flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide or dexamethasone, for the treatment of asthma or COPD | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-12-14 | — | — | US | disclosed |
| EP-2104500-A2 | SUBSTITUTED PIPERIZINES FOR THE TREATMENT OF PAIN | Merck & Co., Inc. (US) | 2009-09-30 | — | — | EP | disclosed |
| US-7569581-B2 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20090155185-A1 | MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC | MEADE CHRISTOPHER JOHN MONTAGUE | 2009-06-18 | — | — | US | disclosed |
| US-5532266-A | Acrylacetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| WO-1995025726-A1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING α-ANTAGONIST ACTIVITY | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-09-28 | — | — | WO | disclosed |
| EP-0362622-B1 | Use of stable oxapenem-3-carboxylic acids for the manufacture of beta-lactamase inhibiting medicaments | LILLY CO ELI (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0569802-A1 | Arylacetamides | MERCK PATENT GmbH (DE) | 1993-11-18 | — | — | EP | disclosed |
| EP-0301394-B1 | STABLE OXAPENEM-3-CARBOXYLIC ACIDS | Pfaendler, Hans Rudolf, Prof. Dr. (DE) | 1993-10-06 | — | — | EP | disclosed |
| EP-0528172-A1 | (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1993-02-24 | — | — | EP | disclosed |
| US-5108747-A | STABLE OXPENEM-3-CARBOXYLIC ACIDS AS BETA-LACTAMASE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1992-04-28 | — | — | US | disclosed |
| US-5096899-A | Nonhydrolyzing oxapenicillins | BAYER AKTIENGESELLSCHAFT (DE) | 1992-03-17 | — | — | US | disclosed |
| US-4713391-A | Azabicyloalkane phenyl substituted alkane carboxylates, their preparation and use as anticholinergic agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1987-12-15 | — | — | US | disclosed |
| US-4140770-A | Benzoylethers and processes for their production | A. NATTERMANN & CIE. GMBH (DE) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395231-A1 | RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | TACR1, TACR2, GPBAR1 | HDAC3 1896/4885HDAC4 2896/4885HDAC1 2097/4885 |
| US-20090155185-A1 | MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC | ADRB2, CHRM3, ADRB1 | HDAC3 3565/4885HDAC4 3560/4885HDAC1 2950/4885 |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | HDAC3 2454/4885HDAC4 3062/4885HDAC1 2244/4885 |
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | EIF2AK2, GTF3C4, GTF3C1 | HDAC3 384/4885HDAC4 535/4885HDAC1 308/4885 |
| US-11905274-B2 | Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof | TACR1, TACR2, GPBAR1 | HDAC3 1896/4885HDAC4 2896/4885HDAC1 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.